Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Designs for efficient clinical trials.

R Simon1

  • 1Biometric Research Branch National Cancer Institute.

Oncology (Williston Park, N.Y.)
|July 1, 1989
PubMed
Summary
This summary is machine-generated.

This review covers efficient statistical designs for clinical trials. It details methods for Phase II and Phase III trials, focusing on patient minimization and early stopping rules to ensure valid treatment effectiveness conclusions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative strain typing of Rhizobium leguminosarum bv. viciae natural populations.

Canadian journal of microbiology·2001
Same author

Impact of 2,4-diacetylphloroglucinol-producing biocontrol strain Pseudomonas fluorescens F113 on intraspecific diversity of resident culturable fluorescent pseudomonads associated with the roots of field-grown sugar beet seedlings.

Applied and environmental microbiology·2001
Same author

Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.

Medical and pediatric oncology·2001
Same author

Control of cell fate in plant meristems.

Novartis Foundation symposium·2001
Same author

A molecular link between stem cell regulation and floral patterning in Arabidopsis.

Cell·2001
Same author

Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes.

Cancer research·2001
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

Area of Science:

  • Clinical Trial Design
  • Biostatistics
  • Pharmaceutical Research

Background:

  • Efficient clinical trial design is crucial for drug development.
  • Previous trial methodologies may not optimize patient enrollment or data analysis.
  • Inappropriate analysis of interim data can lead to false claims of effectiveness.

Purpose of the Study:

  • To review and present efficient statistical designs for Phase II and Phase III clinical trials.
  • To describe methods for minimizing patient numbers in early-stage trials.
  • To outline valid approaches for analyzing sequentially accumulating data and avoiding spurious findings.

Main Methods:

  • Review of two-stage designs for Phase II trials to identify inactive treatments.
  • Description of randomized Phase II designs for selecting optimal experimental regimens.

Related Experiment Videos

  • Presentation of Phase III designs with early stopping rules and valid sequential analysis methods.
  • Discussion of factorial designs for multifactorial treatment comparisons.

    • Main Results:

    • Tabulated two-stage designs effectively minimize patient enrollment for unpromising treatments.
    • Randomized Phase II designs facilitate the selection of superior experimental regimens.
    • Phase III designs offer simple early stopping rules to discontinue ineffective treatments.
    • Methods for valid confidence limit calculation with sequential data are provided.

    Conclusions:

    • The reviewed statistical designs enhance the efficiency of Phase II and Phase III clinical trials.
    • Proper application of sequential analysis is vital for accurate treatment effectiveness assessment.
    • Factorial designs offer a cost-effective approach for evaluating multiple treatment aspects simultaneously.